As mentioned above, the pancreatic adenocarcinoma, especially the basal-like mesenchymal pancreatic ductal adenocarcinoma, presents a unique challenge in cancer therapy due to its distinct and unique immunosuppressive tumor microenvironment, exacerbated by allelic imbalances and high expression levels of oncogenic KRAS [11]. Here, KRAS is linked to pancreatic ductal adenocarcinoma.